Dr. Luke B. Evnin, Ph.D. co-founded MPM Capital in 1997 and serves as its Managing Director and Managing Partner. Dr. Evnin co-founded Maverick Therapeutics, Inc. in 2016 and serves as its Chairman of the Board. He serves as Chairman of the Board and Managing Director at Blade Therapeutics, Inc. He co-founded Cerimon Pharmaceuticals, Inc., in 2004. He co-Founded Amphivena Therapeutics, Inc. in 2013 and serves as its Chairman of the Board. Prior to co-founding MPM, he honed his skills as a venture capitalist beginning in 1990 at Accel Partners for over seven years including four years as a General Partner where he focused on emerging healthcare companies. Mr. Evnin serves as the Chairman of Tizona Therapeutics, Inc. He is a Founder and Chairman of Harpoon Therapeutics, Inc. He has been the Chairman of Oncorus, Inc. since July 19, 2016 and serves as its Director. Mr. Evnin serves as Director at CoStim Pharmaceuticals Inc., Potenza Therapeutics, Inc., Trieza Therapeutics, Inc. He has been a Director of Amphivena Therapeutics, Inc. since July 2013, Syndax Pharmaceuticals, Inc. since May 2012 and NeuroTherapeutics Pharma, Inc. since May 2010. Mr. Evnin serves as a Director of Venturi Group, LLC., and BioValve. He serves as Member of Advisory Board at QB3. Mr. Evnin serves as External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton. He served as a Director of Epic Therapeutics, Inc., CryoCor, Inc., CoTherix, Inc., Peptimmune, Inc., Innovative Spinal Technologies, Inc. and Idun Pharmaceuticals, Inc. Mr. Evnin served as a Member of Supervisory Board of Intercell AG, since July 2004 until February 2006. He served as an Independent Director of Metabasis Therapeutics Inc. since September 2000. Mr. Evnin served as a Director of Cerecor Inc. until April 22, 2015, Pacira Pharmaceuticals, Inc. from December 2006 to September 30, 2013, Oxagen Limited since May 23, 2005, Restore Medical Incorporated since June 2000 and EnteroMedics Inc. from 2002 to May 06, 2015. Mr. Evnin served as Director of EPIX Pharmaceuticals, Inc. He served as Independent Director of Oscient Pharmaceuticals Corp. since February 2004. He served as Director at Atugen, CHF Solutions, Medical SelfCare, Sonic Innovations, EPIX Medical and several other private companies. He served as Director of Otix Global, Inc. Mr. Evnin has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. He has a Ph.D. in the Department of Biochemistry at the University of California-San Francisco and holds an A.B. in Molecular Biology, magna cum laude, from Princeton University. Mr. Evnin also holds Masters in Translational Medicine program at UCSF and the Boston University Scleroderma CORT. Dr. Luke B. Evnin, Ph.D. co-founded MPM Capital in 1997 and serves as its Managing Director and Managing Partner. Dr. Evnin co-founded Maverick Therapeutics, Inc. in 2016 and serves as its Chairman of the Board. He serves as Chairman of the Board and Managing Director at Blade Therapeutics, Inc. He co-founded Cerimon Pharmaceuticals, Inc., in 2004. He co-Founded Amphivena Therapeutics, Inc. in 2013 and serves as its Chairman of the Board. Prior to co-founding MPM, he honed his skills as a venture capitalist beginning in 1990 at Accel Partners for over seven years including four years as a General Partner where he focused on emerging healthcare companies. Mr. Evnin serves as the Chairman of Tizona Therapeutics, Inc. He is a Founder and Chairman of Harpoon Therapeutics, Inc. He has been the Chairman of Oncorus, Inc. since July 19, 2016 and serves as its Director. Mr. Evnin serves as Director at CoStim Pharmaceuticals Inc., Potenza Therapeutics, Inc., Trieza Therapeutics, Inc. He has been a Director of Amphivena Therapeutics, Inc. since July 2013, Syndax Pharmaceuticals, Inc. since May 2012 and NeuroTherapeutics Pharma, Inc. since May 2010. Mr. Evnin serves as a Director of Venturi Group, LLC., and BioValve. He serves as Member of Advisory Board at QB3. Mr. Evnin serves as External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton. He served as a Director of Epic Therapeutics, Inc., CryoCor, Inc., CoTherix, Inc., Peptimmune, Inc., Innovative Spinal Technologies, Inc. and Idun Pharmaceuticals, Inc. Mr. Evnin served as a Member of Supervisory Board of Intercell AG, since July 2004 until February 2006. He served as an Independent Director of Metabasis Therapeutics Inc. since September 2000. Mr. Evnin served as a Director of Cerecor Inc. until April 22, 2015, Pacira Pharmaceuticals, Inc. from December 2006 to September 30, 2013, Oxagen Limited since May 23, 2005, Restore Medical Incorporated since June 2000 and EnteroMedics Inc. from 2002 to May 06, 2015. Mr. Evnin served as Director of EPIX Pharmaceuticals, Inc. He served as Independent Director of Oscient Pharmaceuticals Corp. since February 2004. He served as Director at Atugen, CHF Solutions, Medical SelfCare, Sonic Innovations, EPIX Medical and several other private companies. He served as Director of Otix Global, Inc. Mr. Evnin has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. He has a Ph.D. in the Department of Biochemistry at the University of California-San Francisco and holds an A.B. in Molecular Biology, magna cum laude, from Princeton University. Mr. Evnin also holds Masters in Translational Medicine program at UCSF and the Boston University Scleroderma CORT.

Clinical & Experimental Pathology